NICE rejection of Erbitux in head and neck cancer is final
This article was originally published in Scrip
Using Merck Serono's (Merck KGaA) Erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat patients in England and Wales with recurrent and/or metastatic squamous cell cancer of the head and neck would not be a cost-effective use of UK national health service resources, an assessment agency has found.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.